Fatty liver disease affects a growing number of patients, often progressing silently until advanced stages. This episode highlights what pharmacists need to know about recent terminology changes, risk factors, pharmacotherapy updates, and key counseling strategies to support patients. Tune in to sharpen your clinical knowledge and help identify, manage, and educate patients at risk for this increasingly common condition.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Sarah Wheeler, PharmD, BCACP, CDCES
Assistant Professor
VCU School of Pharmacy


CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current terminology, risk factors, and stages associated with fatty liver disease.
2. Identify evidence-based pharmacologic and non-pharmacologic strategies that pharmacists can use to support patients with or at risk for fatty liver disease.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-219-H01-P
Initial release date: 6/23/2025
Expiration date: 6/23/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram